IQVIA-backed Q2 Solutions completed the acquisition of Nexelis from Ampersand Capital Partners.

IQVIA-backed Q2 Solutions, a provider of clinical trial laboratory services, completed the acquisition of Nexelis, a provider of biomarker testing services, from Ampersand Capital Partners, a middle market private equity firm. Financial terms were not disclosed. “The support and guidance from the Ampersand team on strategy and execution over the past three years has been instrumental to the Nexelis growth story. Together we have built a global organization with leading expertise in immunology and vaccine testing. We are excited to continue to expand our capabilities, capacity and global reach with our biopharma and biotech customers’ needs at the front of mind," Benoit Bouche, Nexelis President & CEO.